Department of Radiation Oncology, University of Colorado Denver, Aurora.
Department of Health Systems, Management and Policy, University of Colorado Cancer Center, Aurora.
JAMA Otolaryngol Head Neck Surg. 2019 Jan 1;145(1):53-61. doi: 10.1001/jamaoto.2018.2974.
Oral cavity squamous cell carcinoma (OCSCC) is associated with often-delayed clinical diagnosis, poor prognosis, and expensive therapeutic approaches. Prognostic accuracy is important in improving treatment outcomes of patients with this disease.
To assess lymph node ratio (LNR) and other factors in estimating response to treatment and provide prognostic information helpful for clinical decision making.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted from January 1, 2000, to December 31, 2015, at an academic hospital in Denver, Colorado. Participants included 149 patients with primary OCSCC who received curative-intent surgery and/or postoperative adjuvant therapies. Analysis was performed from December 8, 2017, to August 15, 2018.
Overall survival (OS), disease-free survival (DFS), locoregional disease-free survival (LRDFS), and distant metastasis-free survival (DMDFS) adjusted for known prognostic risk factors, as well as correlation of LNR with other histopathologic prognostic factors.
Of the 149 patients included in analysis, 105 were men (70.5%); the median age at diagnosis was 59 years (range, 28-88 years). Using the Kaplan-Meier method, the 5-year survival estimates for OS rate was 40.4% (95% CI, 31.3%-49.3%); DFS, 48.6% (95% CI, 38.6%-58.0%); LRDFS, 57.7% (95% CI, 46.6%-67.2%); and DMDFS, 74.7% (95% CI, 65.1%-82.0%). The median follow-up was 20 months for all patients and 34.5 months (range, 0-137 months) for surviving patients. Nonwhite race (hazard ratio [HR], 2.15; 95% CI, 1.22-3.81), T3-T4 category (HR, 1.99; 95% CI, 1.18-3.35), and LNR greater than 10% (HR, 2.71; 95% CI, 1.39-5.27) were associated with poorer OS. Nonwhite patients also had higher risk of locoregional failures (HR, 2.47; 95% CI, 1.28-4.79), whereas women were more likely to have distant metastasis (HR, 2.55; 95% CI, 1.14-5.71). Floor-of-mouth subsite had fewer locoregional recurrences than did other subsites (HR, 0.45, 95% CI, 0.21-0.99). An LNR greater than 10% independently was associated with worse OS (HR, 2.71; 95% CI, 1.39-5.27), DFS (HR, 2.48; 95% CI, 1.18-5.22), and DMDFS (HR, 6.05; 95% CI, 1.54-23.71). The LNR was associated with N-stage (Cramer V, 0.69; 95% CI, 0.58-0.78), extracapsular extension (Cramer V, 0.55; 95% CI, 0.44-0.66), lymphovascular invasion (Cramer V, 0.46; 95% CI, 0.27-0.61); number of excised lymph nodes (Cramer V, 0.24; 95% CI, 0.06-0.37), margin (Cramer V, 0.22; 95% CI, 0.05-0.38), and tumor thickness combined with depth of invasion (Cramer V, 0.25; 95% CI, 0.05-0.38).
Locoregional treatment failure remained the predominant pattern of failure. An advanced pathologic stage and nonwhite race were found to be associated with worse outcomes. The findings from this study suggest that LNR is the most robust prognostic factor and appears to have implications for risk stratification in this disease.
口腔鳞状细胞癌(OCSCC)常伴有延迟的临床诊断、预后不良和昂贵的治疗方法。预后准确性对于改善患者的治疗效果很重要。
评估淋巴结比率(LNR)和其他因素,以估计对治疗的反应,并提供有助于临床决策的预后信息。
设计、地点和参与者:这是一项回顾性队列研究,于 2000 年 1 月 1 日至 2015 年 12 月 31 日在科罗拉多州丹佛市的一家学术医院进行。参与者包括 149 名接受根治性手术和/或术后辅助治疗的原发性 OCSCC 患者。分析于 2017 年 12 月 8 日至 2018 年 8 月 15 日进行。
总生存期(OS)、无病生存期(DFS)、局部区域无病生存期(LRDFS)和无远处转移生存期(DMDFS),调整了已知的预后危险因素,以及 LNR 与其他组织病理学预后因素的相关性。
在纳入分析的 149 名患者中,有 105 名男性(70.5%);诊断时的中位年龄为 59 岁(范围,28-88 岁)。使用 Kaplan-Meier 方法,OS 率的 5 年生存率估计值为 40.4%(95%CI,31.3%-49.3%);DFS 为 48.6%(95%CI,38.6%-58.0%);LRDFS 为 57.7%(95%CI,46.6%-67.2%);DMDFS 为 74.7%(95%CI,65.1%-82.0%)。所有患者的中位随访时间为 20 个月,生存患者的中位随访时间为 34.5 个月(范围,0-137 个月)。非白人种族(风险比[HR],2.15;95%CI,1.22-3.81)、T3-T4 期(HR,1.99;95%CI,1.18-3.35)和 LNR 大于 10%(HR,2.71;95%CI,1.39-5.27)与 OS 较差相关。非白人患者局部区域复发的风险也更高(HR,2.47;95%CI,1.28-4.79),而女性更有可能发生远处转移(HR,2.55;95%CI,1.14-5.71)。口腔底部位的局部区域复发较少,低于其他部位(HR,0.45,95%CI,0.21-0.99)。LNR 大于 10%与 OS(HR,2.71;95%CI,1.39-5.27)、DFS(HR,2.48;95%CI,1.18-5.22)和 DMDFS(HR,6.05;95%CI,1.54-23.71)的不良预后独立相关。LNR 与 N 分期(Cramer V,0.69;95%CI,0.58-0.78)、包膜外扩展(Cramer V,0.55;95%CI,0.44-0.66)、血管淋巴管侵犯(Cramer V,0.46;95%CI,0.27-0.61)、切除的淋巴结数量(Cramer V,0.24;95%CI,0.06-0.37)、切缘(Cramer V,0.22;95%CI,0.05-0.38)和肿瘤厚度合并浸润深度(Cramer V,0.25;95%CI,0.05-0.38)相关。
局部区域治疗失败仍然是主要的失败模式。晚期病理分期和非白人种族与不良结局相关。本研究结果表明,LNR 是最有力的预后因素,并可能对该疾病的风险分层有影响。